Broz P, Dixit VM
In the brain of AD patients, insulin resistance is known to impair glucose metabolism and cause energy deficiency
However, systemic distribution occurs regardless of injection location, so distant injection sites also support healing throughout the body
Clinical trials have demonstrated that Tirzepatide can significantly reduce hemoglobin A1c levelsa critical marker of long-term blood sugar controland assist in weight management
GLP-1RA therapy, when prolonged and potent, may lead to a form of iatrogenic ERM : Short-term gains: lower glucose, lower weight, lower cardiovascular risk Long-term risks: impaired amino-acid balance, reduced re-anabolism, muscle loss, frailty, diminished resilience This progression can be subtle and clinically silentbiochemically detectable long before symptoms appear
Acknowledgments We appreciate the resources provided by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2025R73), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia